U.S. Capital Wealth Advisors LLC Purchases 10,551 Shares of AstraZeneca PLC (NASDAQ:AZN)

U.S. Capital Wealth Advisors LLC lifted its position in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 213.9% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,484 shares of the company's stock after acquiring an additional 10,551 shares during the quarter. U.S. Capital Wealth Advisors LLC's holdings in AstraZeneca were worth $1,138,000 at the end of the most recent reporting period.

Several other hedge funds also recently added to or reduced their stakes in AZN. Callan Capital LLC lifted its position in shares of AstraZeneca by 17.9% during the first quarter. Callan Capital LLC now owns 11,865 shares of the company's stock worth $872,000 after purchasing an additional 1,801 shares during the last quarter. TD Private Client Wealth LLC grew its holdings in shares of AstraZeneca by 11.7% in the first quarter. TD Private Client Wealth LLC now owns 18,767 shares of the company's stock worth $1,379,000 after purchasing an additional 1,959 shares during the last quarter. Envestnet Asset Management Inc. increased its stake in AstraZeneca by 5.5% in the 1st quarter. Envestnet Asset Management Inc. now owns 3,743,066 shares of the company's stock worth $275,115,000 after buying an additional 195,502 shares during the period. Penserra Capital Management LLC lifted its holdings in AstraZeneca by 7.6% during the 1st quarter. Penserra Capital Management LLC now owns 3,183 shares of the company's stock valued at $233,000 after buying an additional 226 shares in the last quarter. Finally, Hendley & Co. Inc. boosted its position in AstraZeneca by 56.1% in the 1st quarter. Hendley & Co. Inc. now owns 73,040 shares of the company's stock valued at $5,368,000 after buying an additional 26,260 shares during the period. 20.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Separately, BNP Paribas started coverage on shares of AstraZeneca in a research report on Tuesday, April 15th. They set an "outperform" rating and a $75.00 target price on the stock. One research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. According to MarketBeat.com, AstraZeneca presently has an average rating of "Moderate Buy" and a consensus price target of $85.00.

AstraZeneca Price Performance

AZN opened at $70.82 on Thursday. The company has a market capitalization of $219.64 billion, a price-to-earnings ratio of 28.44, a PEG ratio of 1.29 and a beta of 0.37. The company has a current ratio of 0.90, a quick ratio of 0.70 and a debt-to-equity ratio of 0.65. AstraZeneca PLC has a 12-month low of $61.24 and a 12-month high of $87.68. The business's fifty day simple moving average is $70.72 and its 200-day simple moving average is $70.71.

AstraZeneca (NASDAQ:AZN - Get Free Report) last issued its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.10 by $0.14. The company had revenue of $13.59 billion for the quarter, compared to analysts' expectations of $13.71 billion. AstraZeneca had a net margin of 14.14% and a return on equity of 33.14%. The firm's quarterly revenue was up 7.2% on a year-over-year basis. During the same period in the prior year, the business earned $2.06 EPS. On average, equities research analysts anticipate that AstraZeneca PLC will post 4.51 earnings per share for the current fiscal year.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.